Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink
{"title":"儿童、青少年和成人肾细胞癌患者接受阿西替尼治疗后的疗效：综述。","authors":"Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink","doi":"10.1016/j.critrevonc.2024.104523","DOIUrl":null,"url":null,"abstract":"<div><div>Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104523"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review\",\"authors\":\"Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink\",\"doi\":\"10.1016/j.critrevonc.2024.104523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"204 \",\"pages\":\"Article 104523\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S104084282400266X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104084282400266X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review
Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.
期刊介绍：
Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
